AI Predictor for ER+/HER2- Breast Cancer

About PathomIQ

PathomIQ is pioneering an AI-driven, interpretable multiomics platform in the diagnostics sector, focusing on transforming precision oncology. Its core asset is a first-of-its-kind phenotype atlas trained on thousands of histopathology slides with corresponding genomic data, enabling the prediction of therapy response, metastasis risk, and gene mutations from routine tissue images. The company positions its solution as a faster, more cost-effective, and tissue-preserving alternative to standalone genomic assays, with demonstrated applications in prostate, triple-negative breast, and ER+/HER2- breast cancers. PathomIQ is a private, likely pre-revenue company seeking to establish its AI-powered predictive tests as a new standard in clinical decision support.

Therapeutic Areas

Other ER+/HER2- Breast Cancer Drugs